Rezultati pretrage - Isabelle Madelaine‐Chambrin
- Prikaz rezultata 1 – 4 od 4
-
1
Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial od Laurence Gérard, A. Bérezné, Lionel Galicier, Véronique Meignin, Martine Obadia, Nathalie De Castro, Christine Jacomet, Renaud Verdon, Isabelle Madelaine‐Chambrin, Emmanuelle Boulanger, Sylvie Chevret, F. Agbalika, Éric Oksenhendler
Izdano 2007Artigo -
2
Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug‐Resistant HIV‐1–Infected Patients: A Randomized Open‐Label Trial od Nathalie De Castro, Joséphine Braun, Isabelle Charreau, Gilles Pialoux, Laurent Cotte, Christine Katlama, François Raffi, Laurence Weiss, Jean‐Luc Meynard, Yazdan Yazdanpanah, Constance Delaugerre, Isabelle Madelaine‐Chambrin, J Aboulker, Jean‐Michel Molina
Izdano 2009Artigo -
3
Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature review od Marie-Léa Gauci, Pauline Laly, Tiphaine Vidal-Trécan, Barouyr Baroudjian, J. Gottlieb, Nika Madjlessi-Ezra, Laetitia Da Meda, Isabelle Madelaine‐Chambrin, M. Bagot, Nicole Basset‐Séguin, Cécile Pagès, Samia Mourah, Philippe Boudou, Célèste Lebbé, Jean‐François Gautier
Izdano 2017Revisão -
4
Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients od Delphine Kérob, Raphaël Porcher, O Vérola, Stéphane Dalle, E. Maubec, F. Aubin, M. D’Incan, Isaak Bodokh, S. Boulinguez, Isabelle Madelaine‐Chambrin, A. Mathieu-Boué, Jean-Marie Servant, É. de Kerviler, Anne Janin, Fabien Calvo, Florence Pédeutour, Célèste Lebbé
Izdano 2010Artigo
Alati za pretragu:
Povezani predmeti
Internal medicine
Medicine
Adverse effect
Chemotherapy
Gastroenterology
Immunology
Surgery
Antibody
Antigen
Antiretroviral therapy
Autoantibody
Biology
Cancer
Chemotherapy regimen
Context (archaeology)
Dermatofibrosarcoma
Dermatofibrosarcoma protuberans
Diabetes mellitus
Discontinuation
Endocrinology
Enfuvirtide
Epitope
Exacerbation
Gp41
Growth factor
Human immunodeficiency virus (HIV)
Imatinib
Imatinib mesylate
Immunotherapy
Insulin